These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35157542)

  • 21. Vaccines and Public Trust: Containing COVID-19 in Cuba.
    Gorry C
    MEDICC Rev; 2022 Jan; 24(1):9-13. PubMed ID: 35157633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA Vaccines in the COVID-19 Pandemic and Beyond.
    Hogan MJ; Pardi N
    Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine development for emerging infectious diseases.
    Excler JL; Saville M; Berkley S; Kim JH
    Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of approved COVID-19 vaccines.
    Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
    Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life.
    Ray SK; Mukherjee S
    Recent Pat Biotechnol; 2022; 16(1):2-5. PubMed ID: 34886784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronavirus Vaccine: Light at the End of the Tunnel.
    Ella KM; Mohan VK
    Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    McGoldrick M; Gastineau T; Wilkinson D; Campa C; De Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Wauters F; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; Collaço de Moraes Stávale M; Sivaramakrishnan VH; Desai S
    Vaccine; 2022 Feb; 40(9):1223-1230. PubMed ID: 35180994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 vaccines: where we stand and challenges ahead.
    Forni G; Mantovani A;
    Cell Death Differ; 2021 Feb; 28(2):626-639. PubMed ID: 33479399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.
    Alonso Ruiz A; Bezruki A; Shinabargar E; Large K; Vieira M; Slovenski I; Liu Y; Agarwal S; Becker A; Moon S
    Global Health; 2024 Mar; 20(1):25. PubMed ID: 38532484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How do we change our approach to COVID with the changing face of disease?
    Apostolopoulos V; Feehan J; Chavda VP
    Expert Rev Anti Infect Ther; 2024 May; 22(5):279-287. PubMed ID: 38642067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa.
    Williams V; Edem B; Calnan M; Otwombe K; Okeahalam C
    Emerg Infect Dis; 2021 Aug; 27(8):2009-2016. PubMed ID: 34138694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fast-tracking development and regulatory approval of COVID-19 vaccines in the EU: A review of ethical implications.
    Beretta G; Marelli L
    Bioethics; 2023 Jun; 37(5):498-507. PubMed ID: 36905651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Pagliusi S; Hayman B; Jarrett S
    Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The COVID-19 experience in Africa and the Middle East.
    Bizri AR; Al Akoury N; Mhlanga T; Morales GDC; Haridy H; Hussey GD; Srivastava A
    Ann Med; 2023 Dec; 55(1):2222641. PubMed ID: 37345635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
    Hanney SR; Wooding S; Sussex J; Grant J
    Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 vaccines: rapid development, implications, challenges and future prospects.
    Kashte S; Gulbake A; El-Amin Iii SF; Gupta A
    Hum Cell; 2021 May; 34(3):711-733. PubMed ID: 33677814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.